Harnessing Btki Therapy By Cdk4/6i Control Of T-cell Surveillance

2024 4:38
Synopsis
Selina Chen-Kiang, PhD, Weill Cornell Medicine, New York City, NY, discusses recent studies investigating palbociclib, a CDK4/6 ...

You Might Also Like

Harnessing BTKi therapy by CDK4/6i control of T-cell surveillance 4:38
Harnessing Btki Therapy By Cdk4/6i Control Of T-cell Surveil...
2024
Resistance Mechanisms Associated With BTK Inhibitors 5:44
Resistance Mechanisms Associated With Btk Inhibitors
2020
Patient Management of CDK 4/6 Inhibitors 10:47
Patient Management Of Cdk 4/6 Inhibitors
2019
Overcoming BTK Resistance With Non-Covalent BTKi 2:19
Overcoming Btk Resistance With Non-covalent Btki
2025
BTK Inhibitors in CLL / SLL 8:55
Btk Inhibitors In Cll / Sll
2026
A Trial Investigating CDK4/6 Inhibitors for the Treatment of Mantle Cell Lymphoma 1:11
A Trial Investigating Cdk4/6 Inhibitors For The Treatment Of...
2019
Targeting B-Cell Receptor Signaling for Anticancer Therapy 2:14
Targeting B-cell Receptor Signaling For Anticancer Therapy
2018
TAKTIC: ipatasertib, endocrine therapy and CDK4/6i for patients with HR+/HER2- mBC 2:07
Taktic: Ipatasertib, Endocrine Therapy And Cdk4/6i For Patie...
2023
The evolving role of non-covalent BTK inhibitors in CLL 1:40
The Evolving Role Of Non-covalent Btk Inhibitors In Cll
2026
What are BTK Inhibitors and Why Are They Different? From the Spring 2023 Education Summit 22:57
What Are Btk Inhibitors And Why Are They Different? From The...
2024
Episode 346: Pharmacology 101: BTK Inhibitors 52:47
Episode 346: Pharmacology 101: Btk Inhibitors
2025
Distinguishing Features Among BTK Inhibitors 3:36
Distinguishing Features Among Btk Inhibitors
2020
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
Ssvid
MP4 & MP3 • HD Quality • Browser Extension Available
Download
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.